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Background: Canadian provinces and territories routinely collect health information for administrative purposes.
This study used Canadian medical and hospital administrative data for population-based surveillance of diagnosed
ischemic heart disease (IHD).
Methods: Hospital discharge abstracts and physician billing claims data from seven provinces were analyzed to
estimate prevalence and incidence of IHD using three validated algorithms: a) one hospital discharge abstract with
an IHD diagnosis or procedure code (1H); b) 1H or at least three physician claims within a one-year period (1H3P)
and c) 1H or at least two physician claims within a one-year period (1H2P). Crude and age-standardized prevalence
and incidence rates were calculated for Canadian adults aged 20 +.
Results: IHD prevalence and incidence varied by province, were consistently higher among males than females,
and increased with age. Prevalence and incidence were lower using the 1H method compared to using the 1H2P
or 1H3P methods in all provinces studied for all age groups. For instance, in 2006/07, crude prevalence by province
ranged from 3.4%-5.5% (1H), from 4.9%-7.7% (1H3P) and from 6.0%-9.2% (1H2P). Similarly, crude incidence by
province ranged from 3.7-5.9 per 1,000 (1H), from 5.0-6.9 per 1,000 (1H3P) and from 6.1-7.9 per 1,000 (1H2P).
Conclusions: Study findings show that incidence and prevalence of diagnosed IHD will be underestimated by as
much as 50% using inpatient data alone. The addition of physician claims data are needed to better assess the
burden of IHD in Canada.
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Ischemic heart disease (IHD) is one of the leading causes
of death in high-income countries worldwide [1]. IHD is
the most costly cardiovascular disease (CVD) in terms of
physician services, hospitalizations, and lost productivity
due to premature death. It accounted for over CDN $8
billion in direct and indirect health care costs in Canada
in 2000 [2]. IHD related hospitalizations and deaths in* Correspondence: Sulan.Dai@phac-aspc.gc.ca
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reproduction in any medium, provided the orCanada have declined markedly since the 1970s [2], pos-
sibly due to a combination of prevention, improved detec-
tion and treatment of the early stages of disease, improved
management of IHD, and more timely and effective treat-
ment of acute events [3-7]. While rates have declined, the
number of people needing treatment has remained high
as the percentage of elderly in the population grows [2].
Currently no formal mechanism to track prevalence
and incidence of IHD exists in Canada. Data sources
such as surveys underestimate the prevalence of chronic
health conditions since the information is self-reported
and institutionalized elderly are commonly not surveyedal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adequately define IHD. Routinely collected administra-
tive hospital data are commonly used for the surveil-
lance of many health conditions in Canada [12-15].
While useful for assessing system performance and
evaluating the quality of health care at the hospital level
[16,17], hospital discharge data alone may be inadequate
for estimating population burden and trends of IHD and
other chronic disease conditions that are often initially
diagnosed and managed in the outpatient setting. There-
fore, combining two administrative health data files: 1)
hospital discharge abstract database, and 2) physician
billing database may provide a more comprehensive de-
scription of diagnosed IHD and may be more suitable
for monitoring the disease burden in the population.
The validity of IHD diagnostic codes in administrative
data has already been evaluated using medical record
reabstraction [18-25] or survey data as the gold standard
[8,26]. A more recent validation study in Ontario used a
sample of family physician Electronic Medical Records
(EMR) as the reference standard [27]. Based on this study,
we chose to assess three case definitions (one hospital dis-
charge abstract and two or three physician claims within a
one-year period). We selected a one-year period for the
second or third physician billing code because allowing
for a two- or three-year period had little impact on the
sensitivity and specificity of the case definition [27] and
the shorter duration allowed for more timely reporting of
surveillance findings. In addition, since previous research
on heart disease surveillance in Canada has relied on hos-
pital discharge data alone [14], we decided to include this
definition for comparison purposes.
Our objective is to describe the process and methods
used to establish national population-based surveillance of
diagnosed IHD using administrative health databases from
seven provinces covering approximately 95% of Canada’s
total population. Specifically, estimates of the incidence
and prevalence of IHD in the Canadian population using
different combinations of hospitalization and/or physician
billing claim databases and their consistency over time
and jurisdiction are presented.
Methods
Study population
The Canadian Chronic Disease Surveillance System
(CCDSS) is a collaborative system for national surveil-
lance supported by the Public Health Agency of Canada
(PHAC), provinces and territories. The CCDSS is cur-
rently expanding its surveillance [28,29] to include IHD
as well as other chronic diseases. Using a standardized
study protocol, feasibility studies were conducted in seven
Canadian provinces (British Columbia (BC), Alberta (AB),
Saskatchewan (SK), Manitoba (MB), Ontario (ON),
Québec (QC), and Nova Scotia (NS)). Algorithms for commondata linkage methods, variable definitions and occurrence
measures were developed by PHAC. These algorithms
were applied to respective provincial administrative health
databases for identification of diagnosed IHD cases among
males and females aged 20 years and older. Individuals
were included in the population under study if they had a
valid health insurance number at any time during the
fiscal year.
Data sources
Records for each individual were linked across the fol-
lowing provincial data sources: 1) provincial health in-
surance registry, 2) hospital discharge abstract database
(inpatient records only), and 3) physician billing data-
base. Linkage was undertaken in each province using a
unique personal identifier.
Demographic information such as sex, date of birth,
date of death, and geographic code were abstracted from
the health insurance registries. These registry files were
also used to derive the denominators (population under
study) for rate calculations, except in Québec where cen-
sus data were used.
In Canada, information about each hospital stay is col-
lected at discharge. Information on IHD was retrieved
from the hospital discharge abstract database using cor-
responding diagnosis or procedure codes, recorded in
any field. The International Classification of Diseases
Ninth Revision (ICD-9), or its Clinical Modification
(ICD-9-CM), or the ICD and Health Related Problems,
Tenth Revision, Canada, referred to as ICD-10-CA, were
used depending on the study year. Corresponding codes
from the Canadian Classification of Diagnostic, Thera-
peutic, and Surgical Procedures (CCP) and ICD-9-CM,
and the Canadian Classification of Health Interventions
(CCI) were used to identify percutaneous coronary inter-
vention (PCI) and coronary artery bypass graft (CABG)
procedures (Table 1).
Physicians’ services performed in hospital, office or
clinic are captured in the physician billing database. In
our study, IHD diagnosis (Table 1) was retrieved from
the first diagnosis field of the physician billing database
coded using ICD-9/ICD-9-CM (except in Ontario, which
uses a modified version based on ICD-8).
Fiscal year 1995/96 (from April 1st to March 31st) was
chosen as the index year, as all provinces had data available
starting in that year. The observation period ended on
March 31, 2007 (herein referred to as 2006/07) as this was
the most recent year of data available for all provinces.
IHD case definitions
Three case definitions were tested. Individuals were con-
sidered a case if in all the years of the study (from 1995/
96 to 2006/07) they had either at least i) one hospital dis-
charge abstract (1H), ii) one hospital discharge abstract or
Table 1 Ischemic heart disease (IHD) case definitions, ICD
codes and procedure codes
CASE DEFINITIONS TESTED
1. One hospital discharge abstract with an IHD diagnostic code or
procedure code in any field
2. One hospital discharge abstract with an IHD diagnostic code or
procedure code in any field OR at least two physician claims within a
one-year period
3. One hospital discharge abstract with an IHD diagnostic code or
procedure code in any field OR at least three physician claims within a
one-year period
ICD codes used to identify occurrences of IHD
ICD-9 or ICD-9-CM ICD-10-CA
IHD 410-414 I20-I25
Health related procedure codes used to identify occurrences of
IHD in the hospital discharge abstract database
CCP ICD-9-CM CCI
PCI 48.02 36.01 1.IJ.50
48.03 36.02 1.IJ.57.GQ
36.05 1.IJ.54
CABG 48.11-48.19 36.10-36.19 1.IJ.76
ICD-9: International Classification of Diseases, Ninth Revision.
ICD-9-CM: Clinical Modification of the Ninth Revision of the International
Classification of Diseases.
ICD-10-CA: International Statistical Classification of Diseases and Related Health
Problems – Tenth Revision, Canada.
PCI: Percutaneous Coronary Intervention.
CABG: Coronary Artery Bypass Graft.
CCP: Canadian Classification of Diagnostic, Therapeutic and Surgical
Procedures (companion classification to ICD-9-CM).
CCI: Canadian Classification of Health Interventions (companion classification
to ICD-10-CA).
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or iii) one hospital discharge abstract or two physician
claims within a one-year period (1H2P) with a diagnosis
code of IHD, or corresponding PCI or CABG codes
(Table 1). The case date was defined as the date of the
hospital discharge (separation) or the last physician claim,
whichever came first.
Statistical analysis
Prevalence estimates were calculated by dividing the total
number of prevalent cases by the insured population and
then multiplying by 100. An individual, who had valid
health insurance and met the criteria for a prevalent case,
remained prevalent for the remainder of the follow-up
period or until death. Cases were defined as ‘incident’ if
the individual was newly diagnosed and never met the
IHD case definition in any of the previous years available
starting in 1995/96. We did not report results obtained be-
tween 1995/96 and 1999/00 in order to avoid misclassify-
ing prevalent cases as incident cases, given that we did not
have historical information for individuals prior to the
index year. Thus, we chose fiscal year 2000/01 to start
reporting results. Incidence rates were calculated bydividing the total number of incident cases by the insured
population with prevalent cases removed, and then multi-
plying by 1,000.
Participating provinces used a standard set of SAS®
macros, developed by PHAC, to calculate disease nu-
merators and denominators. Data were then aggregated
into five-year age groups and transmitted to PHAC
using secure devices. IHD counts and rates were calcu-
lated by PHAC using SAS® Enterprise Guide (Version
4.1, SAS Institute Inc., Cary, North Carolina, 2006). Data
were age-standardized to the 1991 Canadian population
using 5-year age group and 95% confidence intervals
(CI) were computed using an inverse gamma distribu-
tion [30]. Three age groups were created (20-54 years;
55-69 years; 70 + years) to report age-specific rates.
Results
Age-standardized prevalence
Age-standardized prevalence increased from 2000/01 to
2006/07 in all seven provinces and across all three defi-
nitions (Table 2). Overall, in 2006/07, prevalence ranged
by province from 2.7% to 4.4% with the 1H definition,
from 4.2% to 6.1% with the 1H3P definition and from
5.4% to 7.4% with the 1H2P definition (Table 2). Preva-
lence patterns by province and by case definition had
prevalence about 40% lower among females than among
males (not shown).
Crude prevalence
Based on the 1H2P definition, there were almost two mil-
lion individuals aged 20 years and older living with a diag-
nosis of IHD in the seven provinces in 2006/07. The
crude rate by province ranged from 6.0% to 9.2% (1H2P).
Age-specific prevalence showed a similar pattern
across the three case definitions. In the 20-54 age group,
prevalence was lower than 3% in all jurisdictions regard-
less of the definition (Figure 1A). Among individuals
aged 55 to 69 years, prevalence by province ranged from
5.3% to 9.0% (1H), from 8.1% to 12.7% (1H3P), and from
10.8% to 15.4% (1H2P). The highest prevalence was
among individuals aged 70 years and older; it ranged by
province from 15.2% to 23.1% (1H), from 22.0% to 30.4%
(1H3P), and from 26.8% to 35.0% (1H2P).
Age-standardized incidence
Age-standardized incidence decreased in all seven
provinces between 2000/01 and 2006/07 (Table 2).
Overall, in 2006/07, incidence ranged by province from
3.2 to 5.1 per 1,000 population (1H), from 4.5 to 6.4
per 1,000 (1H3P) and from 5.6 per 1,000 to 7.7 per
1,000 (1H2P). Incidence patterns by province and by
case definition also held for both males and females,
with incidence rates 40% lower among females than
among males (not shown).
Table 2 Age-standardized* IHD prevalence (%) and incidence (per 1,000) rates, by case definition, both sexes,
individuals aged 20 years and older in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Québec and Nova
Scotia, 2000/01 and 2006/07
Prevalence (%) Incidence (per 1,000)
2000/01 95% CI 2006/07 95% CI 2000/01 95% CI 2006/07 95% CI
British Columbia
1H 2.4 2.3-2.4 2.7 2.7-2.8 4.7 4.6-4.7 3.2 3.1-3.2
1H or 3P in 1 year 3.6 3.5-3.6 4.2 4.1-4.2 6.5 6.4-6.6 4.5 4.4-4.5
1H or 2P in 1 year 4.6 4.6-4.6 5.4 5.4-5.5 8.1 8.0-8.2 5.7 5.6-5.7
Alberta
1H 3.3 3.2-3.3 3.7 3.7-3.7 6.7 6.5-6.8 4.3 4.3-4.4
1H or 3P in 1 year 4.2 4.2-4.2 4.8 4.8-4.8 7.9 7.8-8.1 5.6 5.5-5.7
1H or 2P in 1 year 5.0 5.0-5.0 5.9 5.9-5.9 9.3 9.2-9.5 6.9 6.8-7.0
Saskatchewan
1H 2.9 2.9-2.9 3.8 3.7-3.8 6.5 6.3-6.7 4.9 4.7-5.0
1H or 3P in 1 year 4.4 4.4-4.5 5.3 5.3-5.4 8.2 8.0-8.4 6.0 5.9-6.2
1H or 2P in 1 year 5.4 5.4-5.5 6.5 6.4-6.6 9.6 9.4-9.8 7.2 7.0-7.4
Manitoba
1H 2.8 2.8-2.8 3.4 3.3-3.4 6.0 5.8-6.2 4.0 3.9-4.1
1H or 3P in 1 year 4.1 4.1-4.2 4.7 4.6-4.7 7.5 7.3-7.7 4.8 4.6-4.9
1H or 2P in 1 year 5.0 4.9-5.0 5.6 5.5-5.6 8.6 8.4-8.8 5.6 5.5-5.8
Ontario
1H 3.1 3.1-3.1 3.5 3.5-3.5 6.3 6.3-6.4 3.9 3.8-3.9
1H or 3P in 1 year 5.2 5.2-5.2 5.7 5.7-5.7 8.9 8.8-9.0 5.8 5.7-5.8
1H or 2P in 1 year 6.4 6.4-6.5 7.2 7.2-7.2 10.7 10.7-10.8 7.2 7.2-7.3
Québec
1H 3.4 3.4-3.4 4.4 4.4-4.4 8.1 8.0-8.2 5.1 5.1-5.2
1H or 3P in 1 year 5.0 5.0-5.1 6.0 5.9-6.0 10.0 9.9-10.1 6.4 6.3-6.5
1H or 2P in 1 year 6.2 6.2-6.2 7.2 7.2-7.3 11.4 11.4-11.5 7.7 7.6-7.8
Nova Scotia
1H 3.9 3.8-3.9 4.4 4.3-4.4 7.0 6.8-7.2 4.3 4.1-4.4
1H or 3P in 1 year 5.5 5.5-5.6 6.1 6.1-6.2 8.9 8.7-9.1 5.8 5.6-5.9
1H or 2P in 1 year 6.5 6.4-6.5 7.4 7.3-7.4 10.3 10.1-10.6 7.1 6.9-7.2
*Rates were standardized for age to the 1991 Canadian population.
1H: one hospital separation; 1H or 3P in 1 year: one hospital separation or three physician billing claims within one year; 1H or 2P in 1 year: one hospital
separation or two physician billing claims within one year. Data source: Canadian Chronic Disease Surveillance System, Public Health Agency of Canada. Data
submitted by provinces in March 2010.
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Using the 1H2P definition, there were over 160,000 indi-
viduals aged 20 years and older in the seven provinces
who received an IHD diagnosis for the first time in
2006/07. The crude rate by province ranged from 6.1 to
7.9 per 1,000 population (1H2P).
Regardless of the case definition, in 2006/07, rates in
all seven provinces were lower than three cases per
1,000 in the 20-54 age group (Figure 1B). In the 55-69 age
group, incidence rates by province ranged from 6.0 to 9.3
per 1,000 (1H), from 8.9 to 11.9 per 1,000 (1H3P) and
from 10.7 to 14.5 per 1,000 (1H2P). Among individualsaged 70 years and older, incidence by province ranged
from 16.4 to 26.9 per 1,000 (1H), from 21.1 to 31.7 per
1,000 (1H3P), and from 25.1 to 35.6 per 1,000 (1H2P).
Discussion
This population-based study demonstrated that the preva-
lence and incidence of IHD were underestimated using
hospital data alone compared with a combination of hos-
pital and physician records. Many IHD cases complaining
of chest pain may not initially go to the hospital and in-
stead consult a family physician for their symptoms
[31-33]. Thus, hospital data are likely to capture severe
Figure 1 Comparisons of IHD case definitions using administrative data. (A) Age-specific IHD prevalence rates (%), by case definition,
individuals aged 20 years and older in British Columbia (BC), Alberta (AB), Saskatchewan (SK), Manitoba (MB), Ontario (ON), Québec (QC) and Nova
Scotia (NS), 2006/07 and (B) Age-specific IHD incidence rates (per 1,000), by case definition, individuals aged 20 years and older in British
Columbia (BC), Alberta (AB), Saskatchewan (SK), Manitoba (MB), Ontario (ON), Québec (QC) and Nova Scotia (NS), 2006/07. Data source: Canadian
Chronic Disease Surveillance System, Public Health Agency of Canada. Data submitted by provinces in March 2010.
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disease. Physician claims not only capture services pro-
vided by family physicians but also services provided by
specialists, regardless of the service location, including
inpatient consultations. Therefore, these two databases
are an invaluable source of information for chronic dis-
ease surveillance.
Accurate estimates of IHD occurrence depends on data
quality. Following the clinical path of the family physician
to specialist and then back to the family physician, we de-
fined IHD in two ways (i.e. at least one hospitalization or
two physician claims within one year and at least one
hospitalization or three physician claims within one year)and found that 1H3P generated slightly lower prevalence
and incidence estimates than 1H2P. Tu et al. assessed the
validity of these two methods using physician chart review
information in Ontario [27]. They found a sensitivity of
77% for 1H2P vs. 72% for 1H3P and a positive predictive
value (PPV) of 75% for 1H2P and 77% for 1H3P. Given a
5% higher sensitivity with 1H2P compared to 1H3P and
minimal impact on PPV, we propose adopting the 1H2P al-
gorithm for the national surveillance of IHD in the CCDSS.
Compared to self-reported data from the 2007-2008
Canadian Community Health Survey (CCHS), crude IHD
prevalence rates estimated with the 1H2P case definition
ranged by province from 6.0% (95% CI: 6.0-6.0) to 9.2%
Robitaille et al. BMC Cardiovascular Disorders 2013, 13:88 Page 6 of 7
http://www.biomedcentral.com/1471-2261/13/88(95% CI: 9.1-9.3) in 2006/07, while CCHS estimates
ranged by province from 3.7% (95% CI: 3.2-4.2) to 7.1%
(95% CI: 6.4-7.8) in 2007-2008. This discrepancy is likely
because individuals who live in collective dwellings such
as long-term care settings and those who are hospitalized
are not captured by the CCHS, but are by administrative
provincial/territorial databases. Moreover, survey data are
sensitive to recall bias; some people may not recall having
been told by a physician that they have IHD.
This study was strengthened by the use of a uniform def-
inition to ascertain diagnosed IHD across seven provinces,
as well as the availability of over ten years of data that
allowed a sufficient clearance time to identify incident
cases. Furthermore, we used a definition that included out-
patients for which the validity has been demonstrated [27].
A few limitations are worth noting. First, although the
inclusion of physician claims may capture earlier stages
of disease, our case definition does not capture undiag-
nosed cases or individuals who die of IHD prior to re-
ceiving a diagnosis, due to the absence of linkage of
hospitalization data to vital statistics. In fact, sensitivity
analyses conducted in Nova Scotia and Québec demon-
strated that capturing fatal AMI events (ICD-9 410 or
ICD-10 I21-I22) using vital statistics would increase inci-
dence rates of AMI by 16% in Nova Scotia and 18% in
Québec. Despite this likely underestimation of the exist-
ence of IHD in the population, the methods established
here and the consistency of results across jurisdictions
are valuable for monitoring trends over time. Second, in-
cidence and prevalence indicators may be sensitive to
changes in rules for reimbursement of health insurance
schemes over time and across provinces or territories. It
will be important to monitor these changes over time
and to conduct periodic revalidation to ensure the integ-
rity of ongoing national surveillance. Third, while our
case definition was validated for the estimation of preva-
lence, we had only 12 years of historical information for
the Canadian population. Thus, some cases identified as
‘incident’ may have been previously diagnosed, leading
to an overestimation of incidence in some categories.Conclusions
The findings of this study indicate that chronic disease
surveillance can benefit from using multiple data
sources, including physician claims and hospital admin-
istrative data. The CCDSS has since been expanded to
include IHD as part of its ongoing national surveillance,
and now has the ability to provide Canadian-wide esti-
mates of IHD prevalence, incidence and all-cause
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